Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLB-001 in Myeloid Malignancies
NCT06378437Phase 1Recruiting
- Sponsor
- GluBio Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLB-001 in polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF) and 2 more (3 arms), sponsored by GluBio Therapeutics. Primary endpoints: Dose-limiting Toxicity up to 28 days, Maximum Tolerated Dose up to 1 year and 4 more. Started May 2024; status: recruiting.
02
Drugs
GLB-001
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)myelofibrosis (MF)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06378437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378437.